Dual HER2 Blockade Helps Prevent Breast Cancer Return

Area of Science:

• Oncology
• Pharmacology

Background:

• Early-stage HER2-positive breast cancer requires effective adjuvant therapies to prevent recurrence.
• Trastuzumab is a standard adjuvant therapy, but further risk reduction is needed for certain patient subgroups.

Purpose of the Study:

• To evaluate the efficacy of adding pertuzumab to trastuzumab-based adjuvant therapy in early-stage HER2-positive breast cancer.
• To identify patient populations who benefit most from this combination regimen.

Main Methods:

• Phase III clinical trial (APHINITY).
• Patients with early-stage HER2-positive breast cancer received adjuvant therapy with trastuzumab plus chemotherapy, with or without pertuzumab.
• Disease recurrence and survival outcomes were assessed.

Main Results:

• The addition of pertuzumab to trastuzumab significantly reduced the risk of disease recurrence.
• A notable benefit was observed in patients with node-positive and hormone receptor-negative disease.
• No new safety concerns were identified with the combination therapy.

Conclusions:

• Pertuzumab in combination with trastuzumab provides a significant reduction in disease recurrence for early-stage HER2-positive breast cancer.
• The combination is particularly beneficial for high-risk subgroups, including node-positive and hormone receptor-negative patients.